高齢者のうつ病について
1Weill Medical College of Cornell University and Weill-Cornell Institute of Geriatric Psychiatry, 21 Bloomingdale Road, White Plains, New York, NY 10605, USA. gsalexop@med.cornell.edu
Lancet (London, England)
|June 7, 2005
まとめ
晩年のうつ病は,高齢者,特に慢性疾患を有する者に対して大きな影響を及ぼします. 有効な治療法はあるが,北米では保険が不十分であるため,高齢者のうつ病の治療へのアクセスを妨げている.
科学分野:
- ゲロントロジーはゲロントロジーの学科です.
- 精神科医は精神病を患っている.
- 神経科学は神経科学である.
背景:
- 晩年のうつ病は,慢性的な疾患と認知障害を持つ高齢者の間で一般的です.
- 深刻な苦しみ,障害,家族の崩壊,死亡率の上昇につながる.
- 老化と病気のプロセスは,気分調節に不可欠な脳の領域に影響を与え,脆弱性を高めます.
研究 の 目的:
- 高齢者におけるうつ病の影響をレビューする.
- 晩年のうつ病に寄与する生物学的および心理的社会的要因について議論する.
- 高齢者のうつ病の現在の治療と予防戦略を評価する.
主な方法:
- 晩年のうつ病に関する研究の文献レビュー.
- 脳の経路に影響する生物学的メカニズム (動脈硬化,炎症,内分泌/免疫の変化) の分析.
- 心理社会的逆境の要因 (貧困,孤立,喪) の検討.
主要な成果:
- 抗うつ薬の治療は,若年層と比較して,高齢者の間でよく耐えられ,有効です.
- 予防と治療のための根拠に基づいたガイドラインとケアシステムがあります.
- 北米では,公共保険が不十分であるため,これらのサービスへのアクセスを制限しています.
結論:
- 高齢者のうつ病は,生物学的および心理的社会的要因の影響を受ける深刻な状態です.
- 有効な介入は存在するが,医療へのアクセスは,保険のカバーが不十分であるため,依然として課題である.
- 介護へのアクセスを改善することは,高齢者のうつ病の管理と予防に不可欠です.
関連する概念動画
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Depressive Disorders: MDD and Dysthymia
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...


